{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:41:34Z","timestamp":1760146894026,"version":"build-2065373602"},"reference-count":45,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT 361426"],"award-info":[{"award-number":["PJT 361426"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Natural killer (NK) and CD8+ T cell function is compromised in human immunodeficiency virus type 1 (HIV-1) infection by increased expression of inhibitory receptors such as TIGIT (T cell immunoreceptor with Ig and ITIM domains). Blocking inhibitory receptors or their ligands with monoclonal antibodies (mAb) has potential to improve antiviral immunity in general and facilitate HIV eradication strategies. We assessed the impact of TIGIT engagement and blockade on cytotoxicity, degranulation, and interferon-gamma (IFN-\u03b3) production by CD8+ T cells from persons living with HIV (PLWH). The effect of TIGIT engagement on non-specific anti-CD3-redirected cytotoxicity was assessed in redirected cytotoxicity assays, and the effect of TIGIT blockade on HIV-specific CD8+ T cell responses was assessed by flow cytometry. In 14\/19 cases where peripheral blood mononuclear cells (PBMC) mediated &gt;10% redirected cytotoxicity, TIGIT engagement reduced the level of cytotoxicity to &lt;90% of control values. We selected PLWH with &gt;1000 HIV Gag or Nef-specific IFN-\u03b3 spot forming cells per million PBMC to quantify the effects of TIGIT blockade on HIV-specific CD8+ T cell responses by flow cytometry. Cell surface TIGIT expression decreased on CD8+ T cells from 23\/40 PLWH following TIGIT blockade and this loss was associated with increased anti-TIGIT mAb fluorescence on monocytes. In total, 6 of these 23 PLWH had enhanced HIV-specific CD8+ T cell degranulation and IFN-\u03b3 production with TIGIT blockade, compared to 0\/17 with no decrease in cell surface TIGIT expression. Reduced CD8+ T cell TIGIT expression with TIGIT blockade involved trogocytosis by circulating monocytes, suggesting that an effector monocyte population and intact fragment crystallizable (Fc) functions are required for mAb-based TIGIT blockade to effectively enhance HIV-specific CD8+ T cell responses.<\/jats:p>","DOI":"10.3390\/pathogens13121137","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T05:58:27Z","timestamp":1734933507000},"page":"1137","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhancement of Human Immunodeficiency Virus-Specific CD8+ T Cell Responses with TIGIT Blockade Involves Trogocytosis"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1380-6519","authenticated-orcid":false,"given":"Nazanin","family":"Ghasemi","sequence":"first","affiliation":[{"name":"Immunology and Infectious Diseases Program, Division of BioMedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John\u2019s, NL A1B 3V6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1544-067X","authenticated-orcid":false,"given":"Kayla A.","family":"Holder","sequence":"additional","affiliation":[{"name":"Immunology and Infectious Diseases Program, Division of BioMedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John\u2019s, NL A1B 3V6, Canada"},{"name":"Department of Biomedical Informatics, University of Colorado School of Medicine, Denver, CO 80045, USA"},{"name":"Department of Immunology and Microbiology, University of Colorado School of Medicine, Denver, CO 80045, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle P.","family":"Ings","sequence":"additional","affiliation":[{"name":"Immunology and Infectious Diseases Program, Division of BioMedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John\u2019s, NL A1B 3V6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0377-2036","authenticated-orcid":false,"given":"Michael D.","family":"Grant","sequence":"additional","affiliation":[{"name":"Immunology and Infectious Diseases Program, Division of BioMedical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St. John\u2019s, NL A1B 3V6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Samji, H., Cescon, A., Hogg, R.S., Modur, S.P., Althoff, K.N., Buchacz, K., Burchell, A.N., Cohen, M., Gebo, K.A., and Gill, M.J. (2013). Closing the gap: Increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0081355"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/ije\/dyh307","article-title":"Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: Emerging role of hepatitis and cancers, persistent role of AIDS","volume":"34","author":"Lewden","year":"2005","journal-title":"Int. J. Epidemiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/cid\/cir626","article-title":"Morbidity and aging in HIV-infected persons: The Swiss HIV cohort study","volume":"53","author":"Hasse","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/ageing\/afq083","article-title":"The ageing of HIV: Implications for geriatric medicine","volume":"39","author":"Kearney","year":"2010","journal-title":"Age Ageing"},{"key":"ref_5","first-page":"118","article-title":"Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy","volume":"17","author":"Deeks","year":"2009","journal-title":"Top. HIV Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev-med-042909-093756","article-title":"HIV infection, inflammation, immunosenescence, and aging","volume":"62","author":"Deeks","year":"2011","journal-title":"Annu. Rev. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/gerona\/glt168","article-title":"Is HIV a model of accelerated or accentuated aging?","volume":"69","author":"Pathai","year":"2014","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.exger.2006.12.003","article-title":"Accelerated immune senescence and HIV-1 infection","volume":"42","author":"Appay","year":"2007","journal-title":"Exp. Gerontol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11904-009-0038-4","article-title":"Early immune senescence in HIV disease","volume":"7","author":"Desai","year":"2010","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Fuertes Marraco, S.A., Neubert, N.J., Verdeil, G., and Speiser, D.E. (2015). Inhibitory Receptors Beyond T Cell Exhaustion. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00310"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: A common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Gubser, C., Chiu, C., Lewin, S.R., and Rasmussen, T.A. (2022). Immune checkpoint blockade in HIV. EBioMedicine, 76.","DOI":"10.1016\/j.ebiom.2022.103840"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Tauriainen, J., Scharf, L., Frederiksen, J., Naji, A., Ljunggren, H.G., Sonnerborg, A., Lund, O., Reyes-Teran, G., Hecht, F.M., and Deeks, S.G. (2017). Perturbed CD8+ T cell TIGIT\/CD226\/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. Sci. Rep., 7.","DOI":"10.1038\/srep40354"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Yin, X., Liu, T., Wang, Z., Ma, M., Lei, J., Zhang, Z., Fu, S., Fu, Y., Hu, Q., and Ding, H. (2018). Expression of the Inhibitory Receptor TIGIT Is Up-Regulated Specifically on NK Cells With CD226 Activating Receptor From HIV-Infected Individuals. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02341"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/eji.200940234","article-title":"Loss of DNAM-1 contributes to CD8+ T-cell exhaustion in chronic HIV-1 infection","volume":"40","author":"Cella","year":"2010","journal-title":"Eur. J. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/QAD.0000000000002488","article-title":"TIGIT is upregulated by HIV-1 infection and marks a highly functional adaptive and mature subset of natural killer cells","volume":"34","author":"Vendrame","year":"2020","journal-title":"Aids"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zhang, X., Lu, X., Cheung, A.K.L., Zhang, Q., Liu, Z., Li, Z., Yuan, L., Wang, R., Liu, Y., and Tang, B. (2021). Analysis of the Characteristics of TIGIT-Expressing CD3\u2212CD56+NK Cells in Controlling Different Stages of HIV-1 Infection. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.602492"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bunet, R., Nayrac, M., Ramani, H., Sylla, M., Durand, M., Chartrand-Lefebvre, C., Routy, J.P., Landay, A.L., Gauchat, J.F., and Chomont, N. (2021). Loss of CD96 Expression as a Marker of HIV-Specific CD8+ T-Cell Differentiation and Dysfunction. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.673061"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e1348","DOI":"10.1002\/cti2.1348","article-title":"TIGIT blockade enhances NK cell activity against autologous HIV-1-infected CD4+ T cells","volume":"10","author":"Holder","year":"2021","journal-title":"Clin. Transl. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Chew, G.M., Fujita, T., Webb, G.M., Burwitz, B.J., Wu, H.L., Reed, J.S., Hammond, K.B., Clayton, K.L., Ishii, N., and Abdel-Mohsen, M. (2016). TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. PLoS Pathog., 12.","DOI":"10.1371\/journal.ppat.1005349"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Holder, K.A., and Grant, M.D. (2020). TIGIT Blockade: A Multipronged Approach to Target the HIV Reservoir. Front. Cell Infect. Microbiol., 10.","DOI":"10.3389\/fcimb.2020.00175"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"15016","DOI":"10.1073\/pnas.0801497105","article-title":"Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade","volume":"105","author":"Blackburn","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Peligero, C., Argilaguet, J., Guerri-Fernandez, R., Torres, B., Ligero, C., Colomer, P., Plana, M., Knobel, H., Garcia, F., and Meyerhans, A. (2015). PD-L1 Blockade Differentially Impacts Regulatory T Cells from HIV-Infected Individuals Depending on Plasma Viremia. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1005270"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1158\/1535-7163.MCT-20-0464","article-title":"Restoration of T-cell Effector Function, Depletion of Tregs, and Direct Killing of Tumor Cells: The Multiple Mechanisms of Action of a-TIGIT Antagonist Antibodies","volume":"20","author":"Preillon","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1007\/s00262-021-02921-8","article-title":"COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade","volume":"70","author":"Hansen","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100433","DOI":"10.1016\/j.ctarc.2021.100433","article-title":"Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody","volume":"28","author":"Shirasuna","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"ref_30","first-page":"514","article-title":"Cancer Immunotherapy, Part 3: Challenges and Future Trends","volume":"42","author":"Ventola","year":"2017","journal-title":"Pharm. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1182\/blood-2014-10-569244","article-title":"Fcgamma-receptor-mediated trogocytosis impacts mAb-based therapies: Historical precedence and recent developments","volume":"125","author":"Taylor","year":"2015","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e0027324","DOI":"10.1128\/jvi.00273-24","article-title":"Immune restoration by TIGIT blockade is insufficient to control chronic SIV infection","volume":"98","author":"Webb","year":"2024","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41586-024-07121-9","article-title":"Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T(reg) cells","volume":"627","author":"Guan","year":"2024","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"101184","DOI":"10.1016\/j.esmoop.2023.101184","article-title":"Anti-TIGIT therapies for solid tumors: A systematic review","volume":"8","author":"Rousseau","year":"2023","journal-title":"ESMO Open"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Joo, V., Petrovas, C., de Leval, L., Noto, A., Obeid, M., Fenwick, C., and Pantaleo, G. (2023). A CD64\/FcgammaRI-mediated mechanism hijacks PD-1 from PD-L1\/2 interaction and enhances anti-PD-1 functional recovery of exhausted T cells. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1213375"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nature19330","article-title":"Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy","volume":"537","author":"Im","year":"2016","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41577-019-0223-7","article-title":"Precursor exhausted T cells: Key to successful immunotherapy?","volume":"20","author":"Kallies","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","article-title":"Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma","volume":"175","author":"Yizhak","year":"2018","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1038\/s41467-021-23324-4","article-title":"Interpretation of T cell states from single-cell transcriptomics data using reference atlases","volume":"12","author":"Andreatta","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1006\/clin.1995.1151","article-title":"A CD3+CD8+ T cell population lacking CD5 antigen expression is expanded in peripheral blood of human immunodeficiency virus-infected patients","volume":"77","author":"Indraccolo","year":"1995","journal-title":"Clin. Immunol. Immunopathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.4049\/jimmunol.171.9.4528","article-title":"CD8+ alpha beta+ T cells that lack surface CD5 antigen expression are a major lymphotactin (XCL1) source in peripheral blood lymphocytes","volume":"171","author":"Stievano","year":"2003","journal-title":"J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.immuni.2010.08.002","article-title":"Differentiation and persistence of memory CD8+ T cells depend on T cell factor 1","volume":"33","author":"Zhou","year":"2010","journal-title":"Immunity"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1742-6405-11-30","article-title":"Greater frequency of CD5-negative CD8+ T cells against human immunodeficiency virus type 1 than other viruses is consistent with adaptation to antigenic variation","volume":"11","author":"Penney","year":"2014","journal-title":"AIDS Res. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat. Immunol."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/12\/1137\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:58:19Z","timestamp":1760115499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/12\/1137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":45,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["pathogens13121137"],"URL":"https:\/\/doi.org\/10.3390\/pathogens13121137","relation":{},"ISSN":["2076-0817"],"issn-type":[{"type":"electronic","value":"2076-0817"}],"subject":[],"published":{"date-parts":[[2024,12,23]]}}}